EichorEICHOR
Study identifier: NCT02688517 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: Recruiting

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Condition: Malignant Neoplasm  ·  Sponsor: Rutgers, The State University of New Jersey

PhaseN/A
Planned participants1100
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNoCheck eligibility criteria ↓
Where11 locations

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Office  ·  732-235-2465

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Karnofsky/Lansky performance score \>= 30 * A signed written informed consent * Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment * Paraffin blocks of the patient's tumor tissue are available and accessible for analysis Exclusion Criteria: * Karnofsky/Lansky performance score \< 30 * Life expectancy \< 3 months

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (11)

Ocean Medical CenterBrick, New Jersey, United StatesCompleted
Bayshore Community HospitalHolmdel, New Jersey, United StatesCompleted
RWJBarnabas Health - Jersey City Medical Center, Jersey CityJersey City, New Jersey, United StatesRecruiting
Southern Ocean County Medical CenterManahawkin, New Jersey, United StatesCompleted
Morristown Medical CenterMorristown, New Jersey, United StatesCompleted
Jersey Shore Medical CenterNeptune City, New Jersey, United StatesCompleted
Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey, United StatesRecruiting
Riverview Medical Center/Booker Cancer CenterRed Bank, New Jersey, United StatesCompleted
Riverview Medical CenterRed Bank, New Jersey, United StatesActive Not Recruiting
Overlook HospitalSummit, New Jersey, United StatesCompleted
University of Wisconsin Hospital and ClinicsMadison, Wisconsin, United StatesWithdrawn

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Jersey CityNew BrunswickBrickHolmdel

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →